A Regeneron preclinical study found that pairing the HER2‑targeted drug Enhertu with a bispecific antibody cleared tumors in mice and provoked lasting immune protection.
A Regeneron preclinical study found that pairing the HER2‑targeted drug Enhertu with a bispecific antibody cleared tumors in mice and provoked lasting immune protection.